Evidence map›Paper›PMID 37559894›Full record

ArticleJournal of asthma and allergy2023

Health Care Situation in the Treatment of Uncontrolled GINA Step 4/5 Patients in Germany.

Hartmut Timmermann, Katrin Milger, Johann Christian Virchow, Olaf Schmidt, Karl-Christian Bergmann, Dirk Koschel, Claus Neurohr, Florian Scholz, Sebastian Heck, Dirk Skowasch

Abstract read
In one paragraph

Article in Journal of asthma and allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hartmut TimmermannSchwerpunktpraxis Colonnaden, Hamburg, Germany.
Katrin MilgerMedicine V, Ludwig-Maximilians-University (LMU) Munich, Member of the German Center for Lung Research (DZL), Comprehensive Pneumology Center Munich (CPC-M), Munich, Germany.ORCID 0000-0003-2914-8773
Johann Christian VirchowAbteilungen für Pneumologie / Intensivmedizin, Universitätmedizin Rostock, Rostock, Germany.
Olaf SchmidtStudienzentrum KPPK, Pneumologische Gemeinschaftspraxis, Koblenz, Germany.
Karl-Christian BergmannInstitute of Allergology, Charité-Universitätsmedizin, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Corporate Member of Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany.
Dirk KoschelFachkrankenhaus Coswig, Lung Centre, Coswig, and Division of Pulmonology, Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany.
Claus NeurohrAbteilung für Pneumologie und Beatmungsmedizin, Robert-Bosch-Krankenhaus Lungenzentrum Stuttgart, Stuttgart, Germany.
Florian ScholzIQVIA Commercial GmbH & Co. OHG, Frankfurt am Main, Germany.
Sebastian HeckGlaxoSmithKline GmbH & Co. KG, Munich, Germany.
Dirk SkowaschDepartment of Internal Medicine II - Pneumology, University Hospital Bonn, Bonn, Germany.ORCID 0000-0003-2377-5936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: It has been estimated that, in 2019, 54,000 patients in Germany had uncontrolled GINA step 4/5 asthma. In the current study we analyzed which health care providers were involved in the management of these patients and their role in disease phenotyping. Patients and Methods: The year 2019 was retrospectively analyzed using the IQVIA Results: Of 54,000 uncontrolled GINA step 4/5 asthma patients in Germany, 52% had consulted both general practitioners (GPs) and pulmonologists, and 48% were seen exclusively by a GP. Of these 54,000 patients, 45% were being prescribed and were thus overusing short-acting β2-agonists (SABAs) and oral corticosteroids (OCS) for ≥2 years, 26% for ≥3 years, and 16% for ≥4 years. In most regions, pulmonologists saw one of their uncontrolled GINA step 4/5 asthma patients per week. Laboratory tests from consultations with a GP were available for only 10% of patients referred to a pulmonologist. In 50% of uncontrolled asthma patients treated according to GINA step 4/5, these were initiated by the pulmonologist, and 34% received laboratory testing within the first year (in GINA step 4/5 asthma, the numbers are 20% and 18%, respectively). Conclusion: Fifty percent of uncontrolled asthma patients treated according to GINA step 4/5 were regularly seen by pulmonologists, who performed most of the phenotyping confirming their importance in the management of severe, uncontrolled asthma in Germany. To understand treatment pathways for these patients, further studies are needed.

Indexed as

biological treatmentGermanylaboratory testprescription databaseuncontrolled GINA step 4/5 asthma

Identifiers

PMID37559894
PMCPMC10408659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.